AI-powered device to identify low LV ejection fraction gains FDA 510(k) clearance
Related Articles
Anumana Demonstrates Global Readiness with Receipt of ISO 13485 Certification
Anumana Demonstrates Global Readiness with Receipt of ISO 13485 CertificationCAMBRIDGE, Mass. – May 21, 2024 – Anumana, a leading AI-driven health technology company and portfolio company of nference, announced today…May 21, 2024
Anumana Receives U.S. FDA Breakthrough Device Designation for its Cardiac Amyloidosis Algorithm
DAIC: Anumana, Inc., a leading AI-driven health technology company, has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its ECG-AI algorithm designed to aid the…June 21, 2023
StartUp Health Insights: Virta & 1Doc3 Close Rounds, Over $1.4B Raised This Week
Health Transformer: Anumana, a startup designing neural network algorithms to enable early detection and accelerate treatment of heart disease, raised $25.7M led by founders nference and Mayo Clinic, with participation…April 20, 2021
Anumana’s AI algorithm for cardiac amyloidosis gets FDA breakthrough nod
Bioworld: Anumana Inc. has garnered a U.S. FDA breakthrough device designation for its artificial intelligence (AI)-powered electrocardiogram-based algorithm for early identification of cardiac amyloidosis. The ECG-AI detection algorithm is the…June 21, 2023